Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer

PURPOSE: Prior clinical trials evaluating cisplatin for non–muscle-invasive bladder cancer (NMIBC) were stopped due to local and systemic toxicity. Currently, there is still a need for improved intravesical therapies, and nanoparticle-based CDDP may be efficacious without the toxicity of free cispla...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Kates, Max, Date, Abhijit, Yoshida, Takahiro, Afzal, Umara, Kanvinde, Pranjali, Babu, Taarika, Sopko, Nikolai A., Matsui, Hotaka, Hahn, Noah M., McConkey, David J., Baras, Alexander, Hanes, Justin, Ensign, Laura, Bivalacqua, Trinity J.
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6487844/
https://ncbi.nlm.nih.gov/pubmed/28808039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1082
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items